CAG
IART icon

Csenge Advisory Group’s Integra LifeSciences IART Stock Holding History

Csenge Advisory Group’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16
Closed – – 756
2018
Q3 		$0 Buy
+16
New +$994 ﹤0.01% 1281

Other funds holding IART

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Csenge Advisory Group's IART Position: Q4 2018 in Review

Csenge Advisory Group sold out of Integra LifeSciences (IART) in Q4 2018, closing a stake of 16 shares.

Csenge Advisory Group first reported a position in IART in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 248 funds tracked by Wall St. Rank hold IART as of Q4 2018.

  • Csenge Advisory Group reported no remaining Integra LifeSciences position as of Q4 2018 after selling out during the quarter.
  • Csenge Advisory Group sold 16 Integra LifeSciences shares in Q4 2018.
  • Csenge Advisory Group first reported a position in Integra LifeSciences in Q3 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Integra LifeSciences position peaked at $0 in Q3 2018.
  • 248 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.